The pharmacological effects of lutein and zeaxanthin on visual disorders and cognition diseases

Molecules

Volumn 22, Issue 4, 2017, Pages

  Jia, Yu Ping ^a   Sun, Lei ^a   Yu, He Shui ^a   Liang, Li Peng ^a   Li, Wei ^a   Ding, Hui ^b   Song, Xin Bo ^a,b   Zhang, Li Juan ^a  

^a TIANJIN UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^b Tianjin Biochemical Pharmaceutical Co Ltd   (China)

Author keywords

ADI; AMD; ARC; Carotenoids; Cataract; Cognition; Lutein; Zeaxanthin

Indexed keywords

XANTHOPHYLL; ZEAXANTHIN;

AGE; ANIMAL; CHEMICAL STRUCTURE; CHEMISTRY; COGNITION; COGNITION DISORDERS; DIETARY SUPPLEMENT; DRUG EFFECTS; HUMAN; MACULAR DEGENERATION; METABOLISM; VISION DISORDERS;

AGE FACTORS; ANIMALS; COGNITION; COGNITION DISORDERS; DIETARY SUPPLEMENTS; HUMANS; LUTEIN; MACULAR DEGENERATION; MOLECULAR STRUCTURE; VISION DISORDERS; ZEAXANTHINS;

EID: 85019668862     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules22040610     Document Type: Review

References (184)

1. Bone, R.A.; Landrum, J.T.; Hime, G.W.; Cains, A.; Zamor, J. Stereochemistry of the human macular carotenoids. Investig. Ophthalmol. Vis. Sci. 1993, 34, 2033-2040.
2. Carotenoids. Handbook; Britton, G.; Liaaen-Jensen, S.; Pfander, H. (Eds.) Birkhäuser Basel: Basel, Switzerland, 2004.
3. Khachik, F.; Beecher, G.R.; Goli, M.B.; Lusby, W.R. Separation, identification, and quantification of carotenoids in fruits, vegetables, and human plasma by high performance liquid chromatography. Pure Appl. Chem. 1991, 63, 71-80. [CrossRef]
4. Khachik, F.; Spangler, C.J.; Smith, J.C.; Canfield, L.M.; Steck, A.; Pfander, H. Identification, quantification, and relative concentrations of carotenoids and their metabolites in human milk and serum. Anal. Chem. 1997, 69, 1873-1881. [CrossRef] [PubMed]
5. Bernstein, P.S. The role of lutein and zeaxanthin in protection against age-related macular degeneration. Acta Hortic. 2015, 1106, 153-160. [CrossRef]
6. Van-De-Kraats, J.; Kanis, M.S.; Van-Norren, D. Lutein and zeaxanthin measured separately in the living human retina with fundus reflectometry. Investig. Ophthalmol. Vis. Sci. 2008, 49, 5568-5573. [CrossRef] [PubMed]
7. Gong, X.; Rubin, L.P. Role of macular xanthophylls in prevention of common neovascular retinopathies: Retinopathy of prematurity and diabetic retinopathy. Arch. Biochem. Biophys. 2015, 572, 40-48. [CrossRef] [PubMed]
8. Renzi, L.M.; Hammond, B.R. The relation between the macular carotenoids, lutein and zeaxanthin, and temporal vision. Ophthalmic Physiol. Opt. 2010, 30, 351-357. [CrossRef] [PubMed]
9. Kijlstra, A.; Tian, Y.; Kelly, E.R.; Berendschot, T.T. Lutein: More than just a filter for blue light. Prog. Retin. Eye Res. 2012, 31, 303-315. [CrossRef] [PubMed]
10. Bone, R.A.; Landrum, J.T.; Tarsis, S.L. Preliminary identification of the human macular pigment. Vis. Res. 1985, 25, 1531-1535. [CrossRef]
11. Arnold, C.;Winter, L.; Fröhlich, K.; Jentsch, S.; Dawczynski, J.; Jahreis, G.; Böhm, V. Macular xanthophylls and !-3 long-chain polyunsaturated fatty acids in age-related macular degeneration: A randomized trial. JAMA Ophthalmol. 2013, 131, 564-572. [CrossRef] [PubMed]
12. Bone, R.A.; Landrum, J.T.; Friedes, L.M.; Gomez, C.M.; Kilburn, M.D.; Menendez, E.; Vidal, I.; Wang, W. Distribution of lutein and zeaxanthin stereoisomers in the human retina. Exp. Eye Res. 1997, 64, 211-218. [CrossRef] [PubMed]
13. Landrum, J.T.; Bone, R.A. Lutein, zeaxanthin, and the macular pigment. Arch. Biochem. Biophys. 2001, 385, 28-40. [CrossRef] [PubMed]
14. Bone, R.A.; Landrum, J.T.; Fernandez, L.; Tarsis, S.L. Analysis of the macular pigment by HPLC: Retinal distribution and age study. Investig. Ophthalmol. Vis. Sci. 1988, 29, 843-849.
15. Handelman, G. J.; Dratz, E.A.; Reay, C.C.; van Kuijk, F.J.G.M. Carotenoids in the human macula and whole retina. Investig. Ophthalmol. Vis. Sci. 1988, 29, 850-855.
16. Wooten, B.R.; Hammond, B.R. Macular pigment: Influence on visual acuity and visibility. Prog. Retin. Eye Res. 2002, 21, 225-240. [CrossRef]
17. Subczynski, W.K.;Wisniewska, A.;Widomska, J. Location of macular xanthophylls in the most vulnerable regions of photoreceptor outer-segment membranes. Arch. Biochem. Biophys. 2010, 504, 61-66. [CrossRef] [PubMed]
18. Nd, B.F.; Snodderly, D.M.; Johnson, E.J.; Schalch, W.; Koepcke, W.; Gerss, J.; Neuringer, M. Nutritional manipulation of primate retinas, V: Effects of lutein, zeaxanthin, and n-3 fatty acids on retinal sensitivity to blue-light-induced damage. Investig. Ophthalmol. Vis. Sci. 2011, 52, 3934-3942.
19. Berrow, E.J.; Bartlett, H.E.; Eperjesi, F.; Gibson, J.M. The effects of a lutein-based supplement on objective and subjective measures of retinal and visual function in eyes with age-related maculopathy-A randomised controlled trial. Br. J. Nutr. 2013, 109, 1-7. [CrossRef] [PubMed]
20. Ham, W.T.; Mueller, H.A.; Sliney, D.H. Retinal sensitivity to damage from short wavelength light. Nature 1976, 260, 153-155. [CrossRef] [PubMed]
21. Bernstein, P.S.; Khachik, F.; Carvalho, L.S.; Carvalho, L.S.; Muir, G.J.; Zhao, D.Y.; Katz, N.B. Identification and quantitation of carotenoids and their metabolites in the tissues of the human eye. Exp. Eye Res. 2001, 72, 215-223. [CrossRef] [PubMed]
22. Granado, F.; Olmedilla, B.; Blanco, I. Nutritional and clinical relevance of lutein in human health. Br. J. Nutr. 2003, 90, 487-502. [CrossRef] [PubMed]
23. Reading, V.M.;Weale, R.A. Macular pigment and chromatic aberration. J. Opt. Soc. Am. 1974, 64, 231-234. [CrossRef] [PubMed]
24. Renzi, L.M.; Hammond, B.R. The effect of macular pigment on heterochromatic luminance contrast. Exp. Eye Res. 2010, 91, 896-900. [CrossRef] [PubMed]
25. Karppi, J.; Laukkanen, J.A.; Kurl, S. Plasma lutein and zeaxanthin and the risk of age-related nuclear cataract among the elderly Finnish population. Br. J. Nutr. 2012, 108, 148-154. [CrossRef] [PubMed]
26. Johnson, E.J. A possible role for lutein and zeaxanthin in cognitive function in the elderly. Am. J. Clin. Nutr. 2012, 96, 1161S-1165S. [CrossRef] [PubMed]
27. Alassane, S.; Binquet, C.; Cottet, V.; Fleck, O.; Acar, N.; Daniel, S.; Delcourt, C.; Bretillon, L.; Bron, A.M.; Creuzot, G.C. Relationships of macular pigment optical density with plasma lutein, zeaxanthin, and diet in an elderly population: The montrachet study. Investig. Ophthalmol. V. Sci. 2016, 57, 1160. [CrossRef] [PubMed]
28. Landrum, J.T.; Bone, R.A.; Moore, L.L.; Gomez, C.M. Analysis of zeaxanthin distribution within individual human retinas. Methods Enzymol. 1999, 299, 457-467. [PubMed]
29. Snodderly, D.M.; Auran, J.D.; Delori, F.C. The macular pigment. II. Spatial distribution in primate retinas. Investig. Ophthalmol. V. Sci. 1984, 25, 674-685.
30. Sommerburg, O.; Siems, W.G.; Hurst, J.S.; Lewis, J.W.; Kliger, D.S.; van Kuijk, F.J. Lutein and zeaxanthin are associated with photoreceptors in the human retina. Curr. Eye Res. 1999, 19, 491-495. [CrossRef] [PubMed]
31. Gass, J.D.M. Müller cell cone, an overlooked part of the anatomy of the fovea centralis: Hypotheses concerning its role in the pathogenesis of macular hole and foveomacualr retinoschisis. Arch. Ophthalmol. 1999, 117, 821-823. [CrossRef] [PubMed]
32. Johnson, E.J. The role of carotenoids in human health. Nutr. Clin. Care 2002, 5, 56-65. [CrossRef] [PubMed]
33. Kim, S.R.; Nakanishi, K.; Itagaki, Y.; Sparrow, J.R. Photooxidation of A2-PE, a photoreceptor outer segment fluorophore, and protection by lutein and zeaxanthin. Exp. Eye Res. 2006, 82, 828-839. [CrossRef] [PubMed]
34. Junghans, A.; Sies, H.; Stahl, W. Macular pigments lutein and zeaxanthin as blue light filters studied in liposomes. Arch. Biochem. Biophys. 2001, 391, 160-164. [CrossRef] [PubMed]
35. Elsm, A.A.; Akhtar, H.; Zaheer, K.; Ali, R. Dietary sources of lutein and zeaxanthin carotenoids and their role in eye health. Nutrients 2013, 5, 1169-1185.
36. Choi, R.Y.; Chortkoff, S.C.; Gorusupudi, A.; Bernstein, P.S. Crystalline maculopathy associated with high-dose lutein supplementation. Jama Ophthalmol. 2016, 134, 1445-1448. [CrossRef] [PubMed]
37. Harikumar, K.B.; Nimita, C.V.; Preethi, K.C.; Kuttan, R.; Deshpande, J. Toxicity profile of lutein and lutein ester isolated from marigold flowers (Tagetes erecta). Int. J. Toxicol. 2008, 27, 1-9. [CrossRef] [PubMed]
38. Snodderly, D.M. Evidence for protection against age-related macular degeneration by carotenoids and antioxidant vitamins. Am. J. Clin. Nutr. 1995, 62, 1448S-1461S. [PubMed]
39. Krinsky, N.I.; Landrum, J.T.; Bone, R.A. Biologic mechanisms of the protective role of lutein and zeaxanthin in the eye. Annu. Rev. Nutr. 2003, 23, 171-201. [CrossRef] [PubMed]
40. Miller, J.W. Age-related macular degeneration revisited-Piecing the puzzle: The LXIX Edward Jackson memorial lecture. Am. J. Ophthalmol. 2013, 155, 1-35. [CrossRef] [PubMed]
41. Moukarzel, A.A.; Bejjani, R.A.; Fares, F.N. Xanthophylls and eye health of infants and adults. Leban. Med. J. 2009, 57, 261-267.
42. El-Sm, A.A.; Young, J.C.; Akhtar, H.; Rabalski, I. Stability of lutein in wholegrain bakery products naturally high in lutein or fortified with free lutein. J. Agric. Food Chem. 2010, 58, 10109-10117.
43. Dachtler, M.; Glaser, T.; Kohler, K.; Albert, K. Combined HPLC-MS and HPLC-NMR on-line coupling for the separation and determination of lutein and zeaxanthin stereoisomers in spinach and in retina. Anal. Chem. 2001, 73, 667-674. [CrossRef] [PubMed]
44. Kull, D.R.; Pfander, H. Isolation and structure elucidation of two (Z)-isomers of lutein from the petals of rape (Brassica napus). J. Agric. Food Chem. 1997, 45, 4201-4203. [CrossRef]
45. Calvo, M.M. Lutein: A valuable ingredient of fruit and vegetables. Crit. Rev. Food Sci. Nutr. 2005, 45, 671-696. [CrossRef] [PubMed]
46. Khachik, F.; de Moura, F.F.; Zhao, D.Y.; Aebischer, C.P.; Bernstein, P.S. Transformations of selected carotenoids in plasma, liver, and ocular tissues of humans and in nonprimate animal models. Investig. Ophthalmol. V. Sci. 2002, 43, 3383-3392.
47. Lim, L.S.; Mitchell, P.; Seddon, J.M.; Holz, F.G.;Wong, T.Y. Age-related macular degeneration. Insight J. Am. Soc. Ophthalmic Regist. Nurses 2012, 379, 1728-1738. [CrossRef]
48. Sparrow, J.R.; Ueda, K.; Zhou, J. Complement dysregulation in AMD: RPE-Bruch's membrane-choroid. Mol. Asp. Med. 2012, 33, 436-445. [CrossRef] [PubMed]
49. Evans, J.R.; Fletcher, A.E.;Wormald, R.P. Age-related macular degeneration causing visual impairment in people 75 years or older in Britain: An add-on study to the Medical Research Council Trial of Assessment and Management of Older People in the Community. Ophthalmology 2004, 111, 513-517. [CrossRef] [PubMed]
50. Jager, R.D. Age-related macular degeneration. N. Engl. J. Med. 2008, 358, 2606-2617. [CrossRef] [PubMed]
51. Friedman, D.S.; O'Colmain, B.J.; Muñoz, B.; Tomany, S.C.; McCarty, C.; de Jong, P.T.; Nemesure, B.; Mitchell, P.; Kempen, J. Prevalence of age-related macular degeneration in the United States. Arch. Ophthalmol. 2004, 122, 564-572. [PubMed]
52. Fernández-Robredo, P.; Sádaba, L.M.; Salinas-Alamán, A.; Recalde, S.; Rodríguez, J.A.; García-Layana, A. Effect of lutein and antioxidant supplementation on VEGF expression, MMP-2 activity, and ultrastructural alterations in apolipoprotein E-deficient mouse. Oxid. Med. Cell. Longev. 2013, 2013, 433-454. [CrossRef] [PubMed]
53. Chew, E.Y.; Clemons, T.E.; Agrón, E.; Sangiovanni, J.P.; Davis, M.D.; Ferris, F.L. Ten-year follow-up of age-related macular degeneration in the age-related eye disease study: AREDS report no. 36. JAMA Ophthalmol. 2014, 132, 272-277. [CrossRef] [PubMed]
54. Richer, S.P.; Stiles, W.; Grahamhoffman, K.; Levin, M.; Ruskin, D.; Wrobel, J.; Park, D.W.; Thomas, C. Randomized, double-blind, placebo-controlled study of zeaxanthin and visual function in patients with atrophic age-related macular degeneration: The Zeaxanthin and Visual Function Study (ZVF) FDA IND #78.973. Optom. J. Am. Optom. Assoc. 2011, 82, 667-680.
55. Ma, L.; Yan, S.F.; Huang, Y.M.; Lu, X.R.; Qian, F.; Pang, H.L.; Xu, X.R.; Zou, Z.Y.; Dong, P.C.; Xiao, X.; et al. Effect of lutein and zeaxanthin on macular pigment and visual function in patients with early age-related macular degeneration. Ophthalmology 2012, 119, 2290-2297. [CrossRef] [PubMed]
56. Khan, M.A.; Gurunadh, V.S. Is sunlight exposure a risk factor for age-related macular degeneration? A systematic review and meta-analysis. Br. J. Ophthalmol. 2013, 97, 389-394. [CrossRef]
57. Bian, Q.; Gao, S.; Zhou, J.; Qin, J.; Taylor, A.; Johnson, E.J.; Tang, G.; Sparrow, J.R.; Gierhart, D.; Shang, F. Lutein and zeaxanthin supplementation reduces photooxidative damage and modulates the expression of inflammation-related genes in retinal pigment epithelial cells. Free Radic. Biol. Med. 2012, 53, 1298-1307. [CrossRef] [PubMed]
58. Obermajer, N.; Jevnikar, Z.; Doljak, B.; Kos, J. Role of cysteine cathepsins in matrix degradation and cell signalling. Connect. Tissue Res. 2008, 49, 193-196. [CrossRef] [PubMed]
59. Xu, X.; Hang, L.; Huang, B.; Wei, Y.; Zheng, S.; Li, W. Efficacy of ethanol extract of Fructus lycii and its constituents lutein/zeaxanthin in protecting retinal pigment epithelium cells against oxidative stress: In vivo and in vitro models of age-related macular degeneration. J. Ophthalmol. 2013, 2013, 862806. [CrossRef] [PubMed]
60. Paraoan, L.; Hiscott, P.; Gosden, C.; Grierson, I. Cystatin C in macular and neuronal degenerations: Implications for mechanism(s) of age-related macular degeneration. Vis. Res. 2010, 50, 737-742. [CrossRef] [PubMed]
61. Treumer, F.; Klettner, A.; Baltz, J.; Hussain, A.A.; Miura, Y.; Brinkmann, R.; Roider, J.; Hillenkamp, J. Vectorial release of matrix metalloproteinases (MMPs) from porcine RPE-choroid explants following selective retina therapy (SRT): Towards slowing the macular ageing process. Exp. Eye Res. 2012, 97, 63-72. [CrossRef] [PubMed]
62. Muni, R.H.; Altaweel, M.; Tennant, M.; Weaver, B.; Kertes, P.J. Agreement among Canadian retina specialists in the determination of treatment eligibility for photodynamic therapy in age-related macular degeneration. Retina 2008, 28, 1421-1426. [CrossRef] [PubMed]
63. Veritti, D.; Sarao, V.; Lanzetta, P. Neovascular age-related macular degeneration. Ophthalmologica 2012, 227, 11-20. [CrossRef] [PubMed]
64. Dhoot, D.S.; Kaiser, P.K. Ranibizumab for age-related macular degeneration. Expert Opin. Biol. Ther. 2012, 12, 371-381. [CrossRef] [PubMed]
65. Chakravarthy, U. Bevacizumab for the treatment of neovascular age-related macular degeneration. Ann. Pharmacother. 2012, 46, 290-296. [CrossRef] [PubMed]
66. Jarrett, S.G.; Boulton, M.E. Consequences of oxidative stress in age-related macular degeneration. Mol. Asp. Med. 2012, 33, 399-417. [CrossRef] [PubMed]
67. Sugino, I.K.; Wang, H.; Zarbin, M.A. Age-related macular degeneration and retinal pigment epithelium wound healing. Mol. Neurobiol. 2003, 28, 177-194. [CrossRef]
68. Mettu, P.S.; Wielgus, A.R.; Ong, S.S.; Cousins, S.W. Retinal pigment epithelium response to oxidant injury in the pathogenesis of early age-related macular degeneration. Mol. Asp. Med. 2012, 33, 376-398. [CrossRef] [PubMed]
69. Zuhal, Y.; Irem, U.N.; Filiz, Y. The role of oxidative stress and antioxidants in the pathogenesis of age-related macular degeneration. Clinics 2011, 66, 743-746.
70. Thornton, J.; Edwards, R.; Mitchell, P.; Harrison, R.A.; Buchan, I.; Kelly, S.P. Smoking and age-related macular degeneration: A review of Association. Eye 2005, 19, 935-944. [CrossRef] [PubMed]
71. Kowluru, R.A.; Menon, B.; Gierhart, D.L. Beneficial effect of zeaxanthin on retinal metabolic abnormalities in diabetic rats. Investig. Ophthalmol. Vis. Sci. 2008, 49, 1645-1651. [CrossRef] [PubMed]
72. Pons, M.; Cousins, S.W.; Csaky, K.G.; Striker, G.; Marin-Castaño, M.E. Cigarette smoke-related hydroquinone induces ilamentous actin reorganization and heat shock protein 27 phosphorylation through p38 and extracellular signal-regulated kinase 1/2 in retinal pigment epithelium: implications for age-related macular degeneration. Am. J. Pathol. 2010, 177, 1198-1213. [PubMed]
73. Klein, R.; Peto, T.; Bird, A.; Vannewkirk, M.R. The epidemiology of age-related macular degeneration. Am. J. Ophthalmol. 2004, 137, 486-495. [CrossRef] [PubMed]
74. Espinosa-Heidmann, D.G.; Sall, J.; Hernandez, E.P.; Cousins, S.W. Basal laminar deposit formation in APO B100 transgenic mice: complex interactions between dietary fat, blue light, and vitamin E. Investig. Ophthalmol. V. Sci. 2004, 45, 260-266. [CrossRef]
75. Catanuto, P.; Espinosaheidmann, D.; Pereirasimon, S.; Espinosa-Heidmann, D.; Pereira-Simon, S.; Sanchez, P.; Salas, P.; Hernandez, E.; Cousins, S.W.; Elliot, S.J. Mouse retinal pigmented epithelial cell lines retain their phenotypic characteristics after transfection with human papilloma virus: A new tool to further the study of RPE biology. Exp. Eye Res. 2009, 88, 99-105. [CrossRef] [PubMed]
76. Seddon, J.M. Genetic and environmental underpinnings to age-related ocular diseases. Investig. Ophthalmol. Vis. Sci. 2013, 54, ORSF28-ORSF30. [CrossRef] [PubMed]
77. Merle, B.M.; Maubaret, C.; Korobelnik, J.F.; Delyfer, M.N.; Rougier, M.B.; Lambert, J.C.; Amouyel, P.; Malet, F.; Le Goff, M.; Dartigues, J.F.; et al. Association of HDL-related loci with age-related macular degeneration and plasma lutein and zeaxanthin: The Alienor study. PLoS ONE 2013, 8, e79848. [CrossRef] [PubMed]
78. Jeganathan, V.S.; Verma, N. Safety and efficacy of intravitreal anti-VEGF injections for age-related macular degeneration. Curr. Opin. Ophthalmol. 2009, 20, 223-225. [CrossRef] [PubMed]
79. Ma, L.; Dou, H.L.;Wu, Y.Q.; Huang, Y.B.; Xu, X.R.; Zou, Z.Y.; Lin, X.M. Lutein and zeaxanthin intake and the risk of age-related macular degeneration: A systematic review and meta-analysis. Br. J. Nutr. 2012, 107, 350-359. [CrossRef] [PubMed]
80. Scripsema, N.K.; Hu, D.N.; Rosen, R.B. Lutein, zeaxanthin, and meso-zeaxanthin in the clinical management of eye disease. J. Ophthalmol. 2015, 2015, 1-13. [CrossRef] [PubMed]
81. Chew, E.Y.; Clemons, T.E.; Sangiovanni, J.P.; Danis, R.P.; Ferris, F.L.; Elman, M.J.; Antoszyk, A.N.; Ruby, A.J.; Orth, D.; Bressler, S.B.; et al. Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression: AREDS2 report No. 3. JAMA Ophthalmol. 2014, 132, 142-149. [CrossRef] [PubMed]
82. Charters, L. AREDS gets another look: Removing beta-carotene, adding lutein/zeaxanthin shows clear benefits. Formulary 2013, 48, 229-229.
83. Chew, E.Y.; Clemons, T.E.; SanGiovanni, J.P.; Danis, R.; Ferris, F.L.; Elman, M.; Antoszyk, A.; Ruby, A.; Orth, D.; Bressler, S.; et al. Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: The Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. J. Am. Med. Assoc. 2013, 309, 2005-2015.
84. NIH Study Provides Clarity on Supplements for Protection against Blinding Eye Disease; National Eye Institute: Washington, DC, USA, 2013.
85. Musch, D.C. Evidence for including lutein and zeaxanthin in oral supplements for age-related macular degeneration. JAMA Ophthalmol. 2014, 132, 139-141. [CrossRef] [PubMed]
86. Murray, I.J.; Makridaki, M.; Rl, V.D.V.; Carden, D.; Parry, N.R.; Berendschot, T.T. Lutein supplementation over a one-year period in early AMD might have a mild beneficial effect on visual acuity: The CLEAR study. Investig. Ophthalmol. V. Sci. 2013, 54, 1781-1788. [CrossRef] [PubMed]
87. Ma, L.; Dou, H.L.; Huang, Y.M.; Huang, Y.M.; Lu, X.R.; Xu, X.R.; Qian, F.; Zou, Z.Y.; Pang, L.H.; Dong, P.C.; et al. Improvement of retinal function in early age-related macular degeneration after lutein and zeaxanthin supplementation: A randomized, double-masked, placebo-controlled trial. Am. J. Ophthalmol. 2012, 154, 625-634. [CrossRef] [PubMed]
88. Woo, J.H.; Sanjay, S.; Eong, K.A. Benefits of early awareness in age-related macular degeneration. Eye 2009, 23, 2271-2271. [CrossRef] [PubMed]
89. Pinazodurán, M.D.; Gómezulla, F.; Arias, L.; Araiz, J.; Casaroli-Marano, R.; Gallego-Pinazo, R.; García-Medina, J.J.; López-Gálvez, M.I.; Manzanas, L.; Salas, A.; et al. Do nutritional supplements have a role in age macular degeneration prevention? J. Ophthalmol. 2014, 2014, 901686-901686.
90. Chew, E.Y. Nutrition effects on ocular diseases in the aging eye. Investig. Ophthalmol. Vis. Sci. 2013, 54, 42-47. [CrossRef] [PubMed]
91. Beatty, S.; Chakravarthy, U.; Nolan, J.M.; Muldrew, K.A.;Woodside, J.V.; Denny, F.; Stevenson, M.R. Secondary outcomes in a clinical trial of carotenoids with coantioxidants versus placebo in early age-related macular degeneration. Ophthalmology 2013, 120, 600-606. [CrossRef] [PubMed]
92. Ho, L.; Van Leeuwen, R.;Witteman, J.C.M.; van Duijn, C.M.; Uitterlinden, A.G.; Hofman, A.; de Jong, P.T.V.M.; Vingerling, J.R.; Klaver, C.C. Reducing the genetic risk of age-related macular degeneration with dietary antioxidants, zinc, and omega-3 fatty acids. Arch. Ophthalmol. 2011, 129, 758-766. [CrossRef] [PubMed]
93. Barker, F.M. Dietary supplementation: Effects on visual performance and occurrence of AMD and cataracts. Curr. Med. Res. Opin. 2010, 26, 2011-2023. [CrossRef] [PubMed]
94. Davis, R.L. Preliminary results in macular pigment optical density associated with and without zeaxanthin and lutein supplementation. Adv. Ophthalmol. Vis. Syst. 2015, 2, 0066. [CrossRef]
95. Cabot, F.; Saad, A.; Mcalinden, C.; Haddad, N.M.; Grise-Dulac, A.; Gatinel, D. Objective assessment of crystalline lens opacity level by measuring ocular light scattering with a double-pass system. Am. J. Ophthalmol. 2013, 155, 629-635. [CrossRef] [PubMed]
96. Stevens, G.A.; White, R.A.; Flaxman, S.R.; Price, H.; Jonas, J.B.; Keeffe, J.; Leasher, J.; Naidoo, K.; Pesudovs, K.; Resnikoff, S.; et al. Global prevalence of vision impairment and blindness: Magnitude and temporal trends, 1990-2010. Ophthalmology 2013, 120, 2377-2384. [CrossRef] [PubMed]
97. Ferrandez, A.M.; Blin, O. Causes and prevalence of visual impairment among adults the United States. Arch. Ophthalmol. 2004, 122, 477-485.
98. Rao, G.N.; Khanna, R.; Payal, A. The global burden of cataract. Curr. Opin. Ophthalmol. 2011, 22, 4-9. [CrossRef] [PubMed]
99. Fernandez, M.M.; Afshari, N.A. Cataracts: We have perfected the surgery, but is it time for prevention? Curr. Opin. Ophthalmol. 2011, 22, 2-3. [CrossRef] [PubMed]
100. Fan, X.; Zhang, J.; Zhang, J.; Theves, M.; Strauch, C.; Nemet, I.; Liu, X.; Qian, J.; Giblin, F.J.; Monnier, V.M. Mechanism of lysine oxidation in human lens crystallins during aging and in diabetes. J. Biol. Chem. 2009, 284, 34618-34627. [CrossRef] [PubMed]
101. Zhang, J.; Yan, H.; Löfgren, S.; Tian, X.; Lou, M.F. Ultraviolet radiation-induced cataract in mice: The effect of age and the potential biochemical mechanism. Investig. Ophthalmol. Vis. Sci. 2012, 53, 7276-7285. [CrossRef] [PubMed]
102. Tan, A.G.; Mitchell, P.; Flood, V.M.; Burlutsky, G.; Rochtchina, E.; Cumming, R.G.; Wang, J.J. Antioxidant nutrient intake and the long-term incidence of age-related cataract: The Blue Mountains Eye Study. Am. J. Clin. Nutr. 2008, 87, 1899-1905. [PubMed]
103. Andley, U.P. Effects of alpha-crystallin on lens cell function and cataract pathology. Curr. Mol. Med. 2009, 9, 887-892. [CrossRef] [PubMed]
104. Neroev, V.V.; Katargina, L.A.; Kogoleva, L.V. The prevention of blindness and visual impairment in children with retinopathy of prematurity. Curr. pediatrics 2015, 14, 265-270. [CrossRef]
105. Selin, J.Z.; Rautiainen, S.; Lindblad, B.E.; Morgenstern, R.;Wolk, A. High-dose supplements of vitamins C and E, low-dose multivitamins, and the risk of age-related cataract: A population-based prospective cohort study of men. Am. J. Epidemiol. 2013, 177, 548-555. [CrossRef] [PubMed]
106. Hennis, A.; Wu, S.Y.; Nemesure, B.; Leske, M.C. Risk factors for incident cortical and posterior subcapsular lens opacities in the Barbados Eye Studies. Arch. Ophthalmol. 2004, 122, 525-530. [CrossRef] [PubMed]
107. Chew, E.Y.; Clemons, T.E.; Agrón, E.; Launer, L.J.; Grodstein, F.; Bernstein, P.S. Effect of omega-3 fatty acids, lutein/zeaxanthin, or other nutrient supplementation on cognitive function: The AREDS2 randomized clinical trial. Jama J. Am. Med. Assoc. 2015, 314, 791-801. [CrossRef] [PubMed]
108. Cruickshanks, K.J. Sunlight exposure and risk of lens opacities in a population-based study. Arch. Ophthalmol. 1998, 116, 714. [CrossRef]
109. Delcourt, C.; Carriere, I.M.; Barberger, G.P.; Schalch, W. Plasma lutein and zeaxanthin and other carotenoids as modifiable risk factors for age-related maculopathy and cataract: the POLA Study. Investig. Ophthalmol. V. Sci. 2006, 47, 2329-2335. [CrossRef] [PubMed]
110. Le, M.; Lin, X.M. Effects of lutein and zeaxanthin on aspects of eye health. J. Sci. Food Agric. 2010, 90, 2-12.
111. Lakshminarayana, R.; Aruna, G.; Sathisha, U.V.; Dharmesh, S.M.; Baskaran, V. Structural elucidation of possible lutein oxidation products mediated through peroxyl radical inducer 2,2′-Azobis (2-methylpropionamidine) dihydrochloride: Antioxidant and cytotoxic influence of oxidized lutein in HeLa cells. Chemico-Biol. Interact. 2013, 203, 448-455. [CrossRef] [PubMed]
112. Ravindran, R.D.; Vashist, P.; Gupta, S.K.; Young, I.S.; Maraini, G.; Camparini, M.; Jayanthi, R.; John, N.; Fitzpatrick, K.E.; Chakravarthy, U.; et al. Inverse association of vitamin C with cataract in older people in India. Ophthalmology 2011, 118, 1958-1965. [CrossRef] [PubMed]
113. Liu, X.H.; Yu, R.B.; Liu, R.; Hao, Z.X.; Han, C.C.; Zhu, Z.H.; Ma, L. Association between lutein and zeaxanthin status and the risk of cataract: A Meta-Analysis. Nutrients 2014, 6, 452-465. [CrossRef] [PubMed]
114. Ghaem, M.H.; Tai, B.C.; Wong, T.Y.; Tai, E.S.; Li, J.; Wang, J.J.; Mitchell, P. Metabolic syndrome and risk of age-related cataract over time: An analysis of interval-censored data using a random-effects model. Investig. Ophthalmol. V. Sci. 2012, 54, 641-646. [CrossRef] [PubMed]
115. Beebe, D.C.; Holekamp, N.M.; Shui, Y.B. Oxidative damage and the prevention of age-related cataracts. Ophthalmic Res. 2010, 44, 155-165. [CrossRef] [PubMed]
116. Kui-Yi, X.; Lou, M.F. Effect of age on the thioltransferase (glutaredoxin) and thioredoxin systems in the human lens. Investig. Ophthalmol. Vis. Sci. 2010, 51, 6598-6604.
117. Gale, C.R.; Hall, N.F.; Phillips, D.I.; Martyn, C.N. Plasma antioxidant vitamins and carotenoids and age-related cataract. Ophthalmology 2001, 108, 1992-1998. [CrossRef]
118. Koo, E.; Chang, J.R.; Agrón, E.; Clemons, T.E.; Sperduto, R.D.; Ferris III, F.L.; Chew, E.Y. Ten-year incidence rates of age-related cataract in the Age-Related Eye Disease Study (AREDS): AREDS report no. 33. Ophthalmic Epidemiol. 2013, 20, 71-81. [CrossRef] [PubMed]
119. Mares, J.A.; Voland, R.; Adler, R.; Tinker, L.; Millen, A.E.; Moeller, S.M.; Blodi, B.; Gehrs, K.M.; Wallace, R.B.; Chappell, R.J.; et al. Healthy diets and the subsequent prevalence of nuclear cataract in women. Arch. Ophthalmol. 2010, 128, 738-749. [CrossRef] [PubMed]
120. Christen, W.G.; Liu, S.; Glynn, R.J.; Gaziano, J.M.; Buring, J.E. Dietary carotenoids, vitamins C and E, and risk of cataract in women: A prospective study. Arch. Ophthalmol. 2008, 126, 102-109. [CrossRef] [PubMed]
121. Von, L.J. Metabolism of carotenoids and retinoids related to vision. J. Biol. Chem. 2012, 287, 1627-1634.
122. Ma, L.; Hao, Z.X.; Liu, R.R.; Yu, R.B.; Shi, Q.; Pan, J.P. A dose-response meta-analysis of dietary lutein and zeaxanthin intake in relation to risk of age-related cataract. Graefe's Arch. Clin. Exp. Ophthalmol. 2014, 252, 63-70. [CrossRef] [PubMed]
123. Johnson, E.J.; Vishwanathan, R. Relationship between serum and brain carotenoids, α-tocopherol, and retinol concentrations and cognitive performance in the oldest old from the Georgia Centenarian Study. J. Aging Res. 2012, 2013, 214-219. [CrossRef] [PubMed]
124. Vishwanathan, R.; Kuchan, M.J.; Sen, S.; Johnson, E.J. Lutein is the predominant carotenoid in infant brain: Preterm infants have decreased concentrations of brain carotenoids. J. Pediatr. Gastroenterol. Nutr. 2014, 59, 659-665. [CrossRef] [PubMed]
125. Johnson, E.J. Role of lutein and zeaxanthin in visual and cognitive function throughout the lifespan. Nutr. Rev. 2014, 72, 605-612. [CrossRef] [PubMed]
126. Feeney, J.; Finucane, C.; Savva, G.M.; Cronin, H.; Beatty, S.; Nolan, J.M.; Kenny, R.A. Low macular pigment optical density is associated with lower cognitive performance in a large, population-based sample of older adults. Neurobiol. Aging 2013, 34, 2449-2456. [CrossRef] [PubMed]
127. Vishwanathan, R.; Iannaccone, A.; Scott, T.M.; Kritchevsky, S.B.; Jennings, B.J.; Carboni, G.; Forma, G.; Satterfield, S.; Harris, T.; Johnson, K.C.; et al. Macular pigment optical density is related to cognitive function in older people. Age Ageing 2014, 43, 271-275. [CrossRef] [PubMed]
128. Ong, S.Y.; Cheung, C.Y.; Li, X.; Lamoureux, E.L.; Ikram, M.K.; Ding, J.; Cheng, C.Y.; Haaland, B.A.; Saw, S.M.; Venketasubramanian, N.; et al. Visual impairment, age-related eye diseases, and cognitive function: The Singapore Malay Eye study. Arch. Ophthalmol. 2012, 130, 895-900. [CrossRef] [PubMed]
129. Rogers, M.A.M.; Langa, K.M. Untreated poor vision: A contributing factor to late-life dementia. Am. J. Epidemiol. 2010, 171, 728-735. [CrossRef] [PubMed]
130. Vishwanathan, R.; Neuringer, M.; Snodderly, D.M.; Schalch, W.; Johnson, E.J. Macular lutein and zeaxanthin are related to brain lutein and zeaxanthin in primates. Nutr. Neurosci. 2013, 16, 21-29. [CrossRef] [PubMed]
131. Johnson, E.J.; McDonald, K.; Caldarella, S.M.; Chung, H.Y.; Troen, A.M.; Snodderly, D.M. Cognitive findings of an exploratory trial of docosahexaenoic acid and lutein supplementation in older women. Nutr. Neurosci. 2015, 11, 75-83. [CrossRef] [PubMed]
132. Sale, A.; Berardi, N.; Maffei, L. Enrich the environment to empower the brain. Trends Neurosci. 2009, 32, 233-239. [CrossRef] [PubMed]
133. Buonocore, G.; Perrone, S.; Bracci, R. Free radicals and brain damage in the newborn. Biol. Neonate 2001, 79, 455-458.
134. Knickmeyer, R.C.; Gouttard, S.; Kang, C.; Evans, D.;Wilber, K.; Smith, K.; Hamer, R.M.; Lin, W.; Gerig, G.; Gilmore, J.H. A structural MRI study of human brain development from birth to 2 years. J. Neurosci. 2008, 28, 12176-12182. [CrossRef] [PubMed]
135. Zimmerman, D. Macular pigment optical density as a possible biomarker for predicting the effects of lutein and zeaxanthin on cognition among young healthy adults. Diss. Theses Gradworks 2014, 52, 2014-2027.
136. Devore, E.E.; Grodstein, F.; van Rooij, F.J.; Hofman, A.; Stampfer, M.J.; Witteman, J.C.; Breteler, M.M. Dietary antioxidants and long-term risk of dementia. Arch. Neurol. 2010, 67, 819-825. [CrossRef] [PubMed]
137. Lindbergh, C.; Terry, D.; Mewborn, C.; Renzi-Hammond, L.; Hammond, B.; Miller, S. Aging and dementia-1lutein and zeaxanthin supplementation improves neurocognitive function in older adults as measured using functional magnetic resonance imaging: A randomized controlled trial. Natl. Acad. Neuropsychol. 2016, 31, 574. [CrossRef]
138. Kuchan, M.; Wang, F.; Geng, Y.; Feng, B.; Lai, C. Lutein stimulates the differentiation of human stem cells to neural progenitor cells in vitro. In Presented at Advances and Controversies in Clinical Nutrition, Washington, DC, USA, 5-7 December 2013.
139. Terry, D.; Duda, B.; Mewborn, C.; Lindbergh, C.; Bovier, E.; Shon, D.; Puente, A.; Chu, K.;Washington, T.; Stapley, L.; et al. Brain activity associated with verbal learning and recall in older adults and its relationship to lutein and zeaxanthin concentrations. Arch. Clin. Neuropsychol. 2014, 29, 506. [CrossRef]
140. Hoffmann, K.; Richer, S.;Wrobel, J.; Chen, E.; Podella, C. A prospective study of neuro-cognitive enhancement with carotenoids in elderly adult males with early age related macular degeneration. Ophthalmol. Res. Int. J. 2015, 4, 1-8. [CrossRef] [PubMed]
141. Fatani, A.J.; Parmar, M.Y.; Abuohashish, H.M.; Ahmed, M.M.; Al-Rejaie, S.S. Protective effect of lutein supplementation on oxidative stress and inflammatory progression in cerebral cortex of streptozotocin-induced diabetes in rats. Neurochem. J. 2016, 10, 69-76. [CrossRef]
142. Nolan, J.M.; Loskutova, E.; Howard, A.N.; Moran, R.; Mulcahy, R.; Stack, J.; Bolger, M.; Dennison, J.; Akuffo, K.O.; Owens, N. Macular pigment, visual function, and macular disease among subjects with Alzheimer's disease: An exploratory study. J. Alzheimer's Dis. 2014, 42, 1191-2002.
143. Renzi, L.M.; Dengler, M.J.; Puente, A.; Miller, L.S.; Hammond, B.R. Relationships between macular pigment optical density and cognitive function in unimpaired and mildly cognitively impaired older adults. Neurobiol. Aging 2014, 35, 1695-1699. [CrossRef] [PubMed]
144. Zimmer, J.P.; Hammond, B.R., Jr. Possible influences of lutein and zeaxanthin on the developing retina. Clin. Ophthalmol. 2007, 1, 25-35. [PubMed]
145. Renzi, L.M.; Bovier, E.R.; Hammond, B.R., Jr. A role for the macular carotenoids in visual motor response. Nutr. Neurosci. 2013, 16, 262-268. [CrossRef] [PubMed]
146. Crabtree, D.V.; Ojima, I.; Geng, X.; Adler, A.J. Tubulins in the primate retina: evidence that xanthophylls may be endogenous ligands for the paclitaxel-binding site. Bioorg. Med. Chem. 2001, 9, 1967-1976. [CrossRef]
147. Ozawa, Y.; Sasaki, M.; Takahashi, N.; Kamoshita, M.; Miyake, S.; Tsubota, K. Neuroprotective effects of lutein in the retina. Curr. Pharm. Des. 2012, 18, 51-56. [CrossRef] [PubMed]
148. Mauer, K.; Mauer, U. Alzheimer. The life of a physician and the career of a disease. Bull. Hist. Med. 2003, 78, 728-730.
149. Markesbery, W.R. The role of oxidative stress in Alzheimer disease. Arch. Neurol. 1999, 56, 1449-1452. [CrossRef] [PubMed]
150. Markesbery, W.R.; Lovell, M.A. Damage to lipids, proteins, DNA, and RNA in mild cognitive impairment. JAMA Neurol. 2007, 64, 954-956. [CrossRef] [PubMed]
151. Johnson, E.J.; Maras, J.E.; Rasmussen, H.M.; Tucker, K.L. Intake of lutein and zeaxanthin differ with age, sex, and ethnicity. J. Am. Dietetic Assoc. 2010, 110, 1357-1362. [CrossRef] [PubMed]
152. Cho, E.; Hankinson, S.E.; Rosner, B.; Willett, W.C.; Colditz, G.A. Prospective study of lutein/zeaxanthin intake and risk of age-related macular degeneration. Am. J. Clin. Nutr. 2008, 87, 1837-1843. [PubMed]
153. O'Neill, M.E.; Carroll, Y.; Corridan, B.; Olmedilla, B.; Granado, F.; Blanco, I.; Vanden Berg, H.; Hininger, I.; Rousell, A.M.; Chopra, M.; et al. A European carotenoid database to assess carotenoid intakes and its use in a five-country comparative study. Br. J. Nutr. 2001, 85, 499-507. [CrossRef] [PubMed]
154. Nebeling, L.C.; Forman, M.R.; Graubard, B.I.; Snyder, R.A. Changes in carotenoid intake in the United States: The 1987 and 1992 National Health Interview Surveys. J. Am. Dietetic Assoc. 1997, 97, 991-996. [CrossRef]
155. Seddon, J.M.; Reynolds, R.; Rosner, B. Associations of smoking, body mass index, dietary lutein, and the LIPC gene variant rs10468017 with advanced age-related macular degeneration. Mol. Vis. 2010, 16, 2412-2424. [PubMed]
156. Wenzela, A.J.; Sheehanb, J.P.; Burkeb, J.D.; Lefsrudc, M.G.; Curran-Celentanob, J. Dietary intake and serum concentrations of lutein and zeaxanthin, but not macular pigment optical density, are related in spouses. Nutr. Res. 2007, 27, 462-469. [CrossRef]
157. Granadolorencio, F.; Olmedillaalonso, B.; Blanconavarro, I.; Botellaromero, F.; Simal-Anton, A. Assessment of carotenoid status and the relation to glycaemic control in type I diabetics: A follow-up study. Eur. J. Clin. Nutr. 2006, 60, 1000-1008. [CrossRef] [PubMed]
158. Ciulla, T.A.; Curran-Celantano, J.; Cooper, D.A.; Hammond, B.R.; Danis, R.P.; Pratt, L.M.; Riccardi, K.A.; Filloon, T.G. Macular pigment optical density in a midwestern sample. Ophthalmology 2001, 108, 730-737. [CrossRef]
159. Lyle, B.J.; Mares-Perlman, J.A.; Klein, B.E.; Klein, R.; Greger, J.L. Antioxidant intake and risk of incident age-related nuclear cataracts in the Beaver Dam Eye Study. Am. J. Epidemiol. 1999, 149, 801-809. [CrossRef] [PubMed]
160. Wang, Z.X.; Liu, M.; Zhang, H.Z.; Gu, Y.G.; Xing, Q.Y.; Lai, J.Q. Dietary carotenoid intake in four seasons in urban and rural communities in Jining. J. Nutr. 2009, 31, 6-10.
161. Wang, Z.; Lin, X. Analysis of dietary lutein and zeaxanthin intake in summer and autumn in Beijing community. Food Nutr. China 2010, 2010, 77-80.
162. Song, X.;Wang, Z. Analysis of carotenoid intake in adult diet. Chin. Public Health 2007, 23, 1378-1380.
163. Zhang, F.; Zhu, Y.; Cai, M. Correlation analysis between dietary intake and serum levels of level in a community of Shanghai. Environ. Occup. Med. 2012, 29, 563-565.
164. Parisi, V.; Tedeschi, M.; Gallinaro, G.; Varano, M.; Saviano, S.; Piermarocchi, S. Carotenoids and antioxidants in age-related maculopathy Italian study: Multifocal electroretinogram modifications after 1 year. Ophthalmology 2008, 115, 324-333. [CrossRef] [PubMed]
165. Richer, S.; Stiles, W.; Statkute, L.; Pulido, J.; Frankowski, J.; Rudy, D.; Pei, K.; Tsipursky, M.; Nyland, J. Double-masked, placebo-controlled, randomized trial of lutein and antioxidant supplementation in the intervention of atrophic age-related macular degeneration: The Veterans LAST study (Lutein Antioxidant Supplementation Trial). Optometry 2004, 75, 216-230. [CrossRef]
166. Cangemi, F.E. TOZAL Study: An open case control study of an oral antioxidant and omega-3 supplement for dry AMD. BMC Ophthalmol. 2007, 7, 1-10. [CrossRef] [PubMed]
167. Rosenthal, J.M.; Kim, J.; de Monastario, F.; Thompson, D.J.; Bone, R.A.; Landrum, J.T.; de Moura, F.F.; Khachik, F.; Chen, H.; Schleicher, R.L.; et al. Dose-ranging study of lutein supplementation in persons aged 60 years or older. Investig. Ophthalmol. Vis. Sci. 2006, 47, 5227-5233. [CrossRef] [PubMed]
168. Weigert, G.; Kaya, S.; Pemp, B.; Sacu, S.; Lasta, M.; Werkmeister, R.M.; Dragostinoff, N.; Simader, C.; Garhöfer, G.; Schmidt-Erfurth, U.; et al. Effects of lutein supplementation on macular pigment optical density and visual acuity in patients with age-related macular degeneration. Investig. Ophthalmol. Vis. Sci. 2011, 52, 8174-8178. [CrossRef] [PubMed]
169. Alves, R.A.; Shao, A. The science behind lutein. Toxicol. Lett. 2004, 150, 57-83. [CrossRef] [PubMed]
170. Olmedilla, B.; Granado, F.; Blanco, I.; Vaquero, M. Lutein, but not alpha-tocopherol, supplementation improves visual function in patients with age-related cataracts: A 2-y double-blind, placebo-controlled pilot study. Nutrition 2003, 19, 21-24. [CrossRef]
171. Ribayamercado, J.D.; Blumberg, J.B. Lutein and zeaxanthin and their potential roles in disease prevention. Int. Symp. Eggs Hum. Health 2004, 23, 567S-587S.
172. Olmedilla, B.; Granado, F.; Blanco, I.; Vaquero, M.; Cajigal, C. Lutein in patients with cataracts and age-related macular degeneration: A long-term supplementation study. J. Sci. Food Agric. 2001, 81, 904-909. [CrossRef]
173. European Food Safety Authority. Scientific opinion on the re-evaluation of lutein (e 161b) as a food additive. EFSA J. 2010, 8, 1678. [CrossRef]
174. Joint, F.A.O. Evaluation of Certain Food Additives: Sixty-Third Report of the Joint FAO/WHO Expert Committee on Food Additives; World Health Organization: Geneva, Switzerland, 2005; pp. 23-26.
175. European Food Safety Authority. Safety, bioavailability and suitability of lutein for the particular nutritional use by infants and young children-Scientific Opinion of the Panel on Dietetic Products, Nutrition and Allergies. EFSA J. 2008, 6, 1-24.
176. Satia, J.A.; Littman, A.; Slatore, C.G.; Galanko, J.A.; White, E. Long-term use of beta-carotene, retinol, lycopene, and lutein supplements and lung cancer risk: Results from the Vitamins and Lifestyle (VITAL) study. Am. J. Epidemiol. 2009, 170, 401-402.
177. Institute of Medicine (US) Panel on Dietary Antioxidants and Related Compounds. Dietary Reference Intakes for Vitamin C, Vitamin E, Selenium, and Carotenoids; National Academies Press: Washington, DC, USA, 2000.
178. Olmedilla, B.; Granado, F.; Southon, S.; Wright, A.J.; Blanco, I.; Gil-Martinez, E.; van den BERG, H.; Thurnham, D.; Corridan, B.; Chopra, M.; et al. A European multicentre, placebo-controlled supplementation study with alpha-tocopherol, carotene-rich palm oil, lutein or lycopene: Analysis of serum responses. Clin. Sci. 2002, 102, 447-456. [CrossRef] [PubMed]
179. Maharshak, N.; Shapiro, J.; Trau, H. Carotenoderma-A review of the current literature. Int. J. Dermatol. 2003, 42, 178-181. [CrossRef] [PubMed]
180. Alholou, S.; Tucker, W.R.; Agron, E.; Clemons, T.E.; Chew, E.Y. The association of statin use with cataract progression using propensity matching in the Age-Related Eye Disease Study 2 (AREDS2). Investig. Ophthalmol. Vis. Sci. 2014, 55, 1675.
181. 13C-labeled and endogenous beta-carotene, lutein, and vitamin A in human plasma. Lipids 2001, 36, 1277-1282. [CrossRef] [PubMed]
182. Lienau, A.; Glaser, T.; Tang, G.; Dolnikowski, G.G.; Grusak, M.A.; Albert, K. Bioavailability of lutein in humans from intrinsically labeled vegetables determined by LC-APCI-MS. J. Nutr. Biochem. 2003, 14, 663-670.
183. Burri, B.J.; Park, J.Y.K. Compartmental models of vitamin a and β-carotene metabolism in women. Adv. Exp. Med. Biol. 1998, 445, 225-237. [PubMed]
184. 13C tracer to quantify the plasma appearance of a physiological dose of lutein in humans. Lipids 2000, 35, 339-348. [CrossRef] [PubMed]